BOK Financial Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

BOK Financial Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-60	Closed	-$2.36K	–	518
2024 Q4	$2.36K	Hold	60	–	–	﹤0.01%	436
2024 Q3	$2.82K	Hold	60	–	–	﹤0.01%	463
2024 Q2	$3.24K	Hold	60	–	–	﹤0.01%	424
2024 Q1	$4.09K	Hold	60	–	–	﹤0.01%	410
2023 Q4	$3.76K	Hold	60	–	–	﹤0.01%	415
2023 Q3	$2.72K	Hold	60	–	–	﹤0.01%	353
2023 Q2	$3.37K	Hold	60	–	–	﹤0.01%	335
2023 Q1	$2.71K	Hold	60	–	–	﹤0.01%	401
2022 Q4	$2.44K	Hold	60	–	–	﹤0.01%	340
2022 Q3	$4K	Hold	60	–	–	﹤0.01%	344
2022 Q2	$4K	Buy	+60	New	+$3.53K	﹤0.01%	350

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BOK Financial Private Wealth's CRSP Position: Q1 2025 in Review

BOK Financial Private Wealth sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 60 shares — an estimated $2.36K sold.

BOK Financial Private Wealth first reported a position in CRSP in Q2 2022 and held it in 11 quarters. The position peaked at $4.09K in Q1 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

BOK Financial Private Wealth reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
BOK Financial Private Wealth sold 60 CRISPR Therapeutics shares in Q1 2025, an estimated $2.36K.
BOK Financial Private Wealth first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 11 quarters.
BOK Financial Private Wealth's CRISPR Therapeutics position peaked at $4.09K in Q1 2024.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on BOK Financial Private Wealth's 13F filing for Q1 2025, filed 14 May 2025.